Advertisement

Topics

Novartis AG Kisqali (Ribociclib) Receives EU Approval As First-Line Treatment For HR+/HER2- Locally Advanced Or Metastatic Breast Cancer In Combination With Any Aromatase Inhibitor

20:00 EDT 23 Aug 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Novartis AG Kisqali (Ribociclib) Receives EU Approval As First-Line Treatment For HR+/HER2- Locally Advanced Or Metastatic Breast Cancer In Combination With Any Aromatase Inhibitor

NEXT ARTICLE

More From BioPortfolio on "Novartis AG Kisqali (Ribociclib) Receives EU Approval As First-Line Treatment For HR+/HER2- Locally Advanced Or Metastatic Breast Cancer In Combination With Any Aromatase Inhibitor"

Advertisement
Quick Search
Advertisement
Advertisement